Shares of UnitedHealth Group (UNH) experienced a modest rebound following an 18% drop after the company withdrew its guidance due to rising costs and the resignation of CEO Andrew Witty. Analysts have maintained largely supportive stances, although they have lowered their price targets. UBS kept its “buy” rating, citing confidence in the company’s long-term growth potential despite current setbacks, and reduced its price target to $400 from $525. Similarly, Oppenheimer retained its “outperform” rating, expecting margins to recover by 2026, and lowered its price target to $400 from $600. Morgan Stanley also maintained its “overweight” rating, expressing confidence in the appointment of former CEO Stephen Hemsley as the right leader to address recent challenges. — new from Investopedia
